Effect of an Antiretroviral Regimen Containing Ritonavir Boosted Lopinavir on Intestinal and Hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected Patients-Reference-Cited by-同舟云学术

Effect of an Antiretroviral Regimen Containing Ritonavir Boosted Lopinavir on Intestinal and Hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected Patients

Published:2008-01-09 Issue:1 Volume:84 Page:75-82
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:
Short-container-title:Clin Pharmacol Ther

Author:

Wyen C,Fuhr U,Frank D,Aarnoutse RE,Klaassen T,Lazar A,Seeringer A,Doroshyenko O,Kirchheiner JC,Abdulrazik F,Schmeisser N,Lehmann C,Hein W,Schömig E,Burger DM,Fätkenheuer G,Jetter A

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Reference49 articles.

1. Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection

2. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers

3. Lopinavir/Ritonavir Induces the Hepatic Activity of Cytochrome P450 Enzymes CYP2C9, CYP2C19, and CYP1A2 But Inhibits the Hepatic and Intestinal Activity of CYP3A as Measured by a Phenotyping Drug Cocktail in Healthy Volunteers

4. The implications of P-glycoprotein in HIV: friend or foe?

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of liver diseases and pharmacological interactions on the transportome involved in hepatic drug disposition;Biochemical Pharmacology;2024-03

2. Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis;Antimicrobial Agents and Chemotherapy;2023-10-18

3. Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance;Pharmacology & Therapeutics;2023-08

4. Pharmacokinetic Drug-Drug Interactions Involving Antiretroviral Agents: An Update;Current Drug Metabolism;2023-07

5. Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug–drug interactions via CYP3A metabolism and transporters;Clinical and Translational Science;2023-01-23